Index

Note: Page numbers of article titles are in boldface type.

A

ABO incompatibility
   extended donors in liver transplantation, 883
Acamprosate
   for substance use disorders, 733
Active infections
   extended donors in liver transplantation, 887–889
Addiction. See also specific types, e.g., Substance use disorders
   treatment of
      options, 732–735
Addiction rehabilitation
   for addiction disorders, 732–733
Adefovir
   lamivudine with
      in posttransplant management in HBV patients, 759
      in posttransplant management in HBV patients, 759
      in pretransplant management in HBV patients, 754–755
Advanced donor age
   extended donors in liver transplantation, 881–883
Age
   advanced donor
      extended donors in liver transplantation, 881–883
Alcohol addiction disorders
   described, 729
Alcohol use
   after liver transplantation for ALD, 740
      predictors of, 743
      described, 729
   in liver transplant patients, 727–751. See also Liver transplant recipients, alcohol
      and substance use in
         treatment of
            liver transplantation in
               future directions in, 744–745
Alcoholic liver disease (ALD)
   described, 729
   liver transplantation for
      alcohol use after
         outcomes related to, 741–742
         predictors of, 743
z1-Antitrypsin deficiency
   in pretransplant patients, 766–767
Antiviral therapy
  for recurrent HCV infection after liver transplantation, 848–853
    preemptive posttransplant therapy, 848–849
    pretransplant therapy, 848
Ascites
  in liver transplant candidates, 786–788
Autoimmune hepatitis, 868–873
  de novo, 872–873
  described, 868
  diagnosis of, 869–870
  epidemiology of, 870
  outcome of, 872
  prognosis of, 872
  recommendations, 873
  recurrence of
    predictors of, 870–872
    treatment of, 872
Autoimmune liver diseases
  recurrent and de novo, 859–878
    autoimmune hepatitis, 868–873
    primary biliary cirrhosis, 859–863
    primary sclerosing cholangitis, 863–868
Azotemia
  prerenal
    in liver transplant recipients
      management of, 807–808

B
Bilirubin
  in MELD score, 686–687
Bone disease
  metabolic
    in liver transplant recipients
      medical management of, 830–832
Breathing
  sleep-disordered
    in pretransplant patients, 772
Buprenorphine
  for substance use disorders, 734
Bupropion
  in smoking cessation, 734–735

C
Calcineurin inhibitors (CNIs)
  for renal dysfunction in liver transplant recipients, 813–815
Cancer. See also specific types
  in liver transplant recipients
    medical management of, 832–835
    tobacco use and, 742–743
Chemotherapy
in cholangiocarcinoma management, 706
Cholangiocarcinoma, **699–715**
- biliary structures in
  - management of, 705
  - classification of, 700–701
  - described, 699
  - diagnosis of, 701–704
  - pathophysiology of, 700–701
  - risk factors for, 699–700
  - staging of, 704–705
  - treatment of, 705–712
    - chemotherapy in, 706
    - liver transplantation in, 708–712
      - described, 708–709
      - posttransplant management, 711–712
      - pretransplant management, 709–711
    - surgical resection in, 706–708
Chronic liver disease
  - complications of, 781
Chronic obstructive pulmonary disease (COPD)
  - in pretransplant patients, 765–766
Chronic viral hepatitis
  - in liver transplant candidates
    - antiviral therapy for, 780
Cirrhosis
  - HCV, 729
    - primary biliary, 859–863. See also Primary biliary cirrhosis
CID. See Cold ischemia time (CIT)
CNIs. See Calcineurin inhibitors (CNIs)
Cold ischemia time (CIT)
  - increased
    - extended donors in liver transplantation, 883
Colon cancer
  - in liver transplant recipients
    - medical management of, 834
COPD. See Chronic obstructive pulmonary disease (COPD)
Creatinine
  - in MELD score, 687–688

D
DCD. See Deceased after cardiac death (DCD)
Deceased after cardiac death (DCD)
  - extended donors in liver transplantation, 880–881
Delta MELD, 692
Diabetes mellitus
  - in liver transplant recipients
    - medical management of, 826–828
    - new-onset
      - after liver transplantation, 816
Disulfiram
for substance use disorders, 733

Drug use
illicit
after liver transplantation, 740–741
injected, 729–730

E

Encephalopathy
hepatic
in liver transplant candidates, 791

End-stage liver disease
physical vs. psychiatric disorders in patients with, 728
substance use disorders in patients with, 728–730

Entecavir
in pretransplant management in HBV patients, 755

Ethical issues
liver transplantation for persons with substance use disorders, 736–737

Extended donors
in liver transplantation, 879–900. See also Liver transplant donors, extended donors

G

Gender
MELD score and, 690–691

Genotype
in pretransplant management in HBV patients, 755–756

Glomerular filtration rate (GFR)
in renal disorders
preoperative estimation in liver transplant recipients, 811–812

H

HBV. See Hepatitis B virus (HBV)
HCC. See Hepatocellular carcinoma (HCC)
HCV. See Hepatitis C virus (HCV)
HE. See Hepatic encephalopathy (HE)

Hepatic encephalopathy (HE)
in liver transplant candidates, 791

Hepatic hydrothorax
in pretransplant patients, 767

Hepatitis
autoimmune, 868–873. See also Autoimmune hepatitis
chronic viral
in liver transplant candidates
antiviral therapy for, 780

Hepatitis B core antibody–positive donor livers
posttransplant management in HBV patients, 759

Hepatitis B immune globulin
in posttransplant management in HBV patients, 758

Hepatitis B virus (HBV)
in liver transplant candidates
antiviral therapy for, 780
liver transplantation for
  current status of, **753–764**
  hepatitis B core antibody-positive donor livers, 759
  posttransplant management, 756–760
  pretransplant management, 753–756
  prevalence of, 753
Hepatitis C virus (HCV)
  in liver transplant candidates
    antiviral therapy for, 780
    prevalence of, 729
Hepatitis C virus (HCV) cirrhosis, 729
Hepatitis C virus (HCV) infection
  recurrent
    after liver transplantation
      diagnosis of, 848
      donor-related and surgical predictors of, 846
      management of, **845–858**
        antiviral therapy in, 848–853. See also Antiviral therapy, for recurrent HCV
        infection after liver transplantation
      immunosuppressive regimens in, 847–848
      retransplantation in, 853
      recipient-related predictors of, 847
      viral kinetics in, 845–846
Hepatitis C virus (HCV)-positive donors
  extended donors in liver transplantation, 885–886
Hepatocellular carcinoma (HCC)
  in liver transplant candidates
    RFA for, 785
    screening for, 784–786
    TACE for, 785–786
  liver transplantation for, **717–725**
    MELD in, 718
    recurrence-free survival after, 719
  primary
    UNOS modified TNM staging classification for, 718
Hepatopulmonary syndrome
  in pretransplant patients, 767–770
Hepatorenal syndrome (HRS)
  defined, 789
  in liver transplant candidates, 789–791
HRS. See Hepatorenal syndrome (HRS)
HTLV-I/II infection. See Human T-cell lymphotrophic virus type I/II (HTLV-I/II) infection
Human T-cell lymphotrophic virus type I/II (HTLV-I/II) infection
  extended donors in liver transplantation, 886–887
Hydrothorax
  hepatic
    in pretransplant patients, 791
Hyperlipidemia
  in liver transplant recipients
    medical management of, 829–830
Hypertension
in liver transplant recipients
   medical management of, 821–824
   portopulmonary
      in pretransplant patients, 770–772

I
Immune globulin
   hepatitis B
      in posttransplant management in HBV patients, 758
Immunosuppressive agents
   for recurrent HCV infection after liver transplantation, 847–848
Infection(s). See also specific types
   active
      extended donors in liver transplantation, 887–889
Injected drug use, 729–730
INR. See International Normalized Ratio (INR)
Interferon
   in pretransplant management in HBV patients, 754
International Normalized Ratio (INR)
   in MELD score, 688
Intrinsic renal disease
   in liver transplant recipients
      management of, 809–811

L
Lamivudine
   adefovir with
      in posttransplant management in HBV patients, 759
      in posttransplant management in HBV patients, 758
      in pretransplant management in HBV patients, 754
Liver disease
   pulmonary complications of
      in pretransplant patients, 765–777
         α1-antitrypsin deficiency, 766–767
         COPD, 765–766
         hepatic hydrothorax, 767
         hepatopulmonary syndrome, 767–770
         portopulmonary hypertension, 770–772
         pretransplant pulmonary evaluation related to, 772–774
         sleep-disordered breathing, 772
Liver disease(s)
   autoimmune
      recurrent and de novo, 859–878. See also specific diseases and Autoimmune
         liver diseases, recurrent and de novo
   chronic
      complications of, 781
   end-stage
      substance use disorders in patients with, 728–730
Liver-kidney transplantation
for renal dysfunction in liver transplant recipients, 812
Liver transplant candidates
care of, 779–806
described, 779–780
with chronic liver disease
ascites, 786–788
care of, 779–806
chronic viral hepatitis
antiviral therapy for, 780
HBV
antiviral therapy for, 780
HCC screening in, 784–786
HCV
antiviral therapy for, 780
HE, 791
HRS, 789–791
osteopenia/osteoporosis, 791
prophylaxis in, 783–784
SBP, 788–789
vaccination for, 791–792
variceal screening and management of, 780, 782–784
methadone-maintained, 738–739
tobacco use in, 730
Liver transplant donors
extended donors, 879–900
described, 879
donor-related issues, 880–889
ABO incompatibility, 883
active infections, 887–889
advanced donor age, 881–883
DCD, 880–881
HCV-positive donors, 885–886
HTLV-I/II infection, 886–887
increased CIT, 883
previous malignancy, 884–885
steatosis, 883–884
surgical technique–related issues, 889–893
living donors, 890–893
split liver transplantation, 889–890
Liver transplant recipients
alcohol and substance use in, 727–751
future directions in, 744–745
diabetes mellitus in
medical management of, 826–828
hyperlipidemia in
medical management of, 829–830
hypertension in
medical management of, 821–824
malignancies in
medical management of, 832–835
Liver (continued)
management of
  medical, 821–843
metabolic bone disease in
  medical management of, 830–832
renal dysfunction in
  management of, 807–820
    CNIs in, 813–815
    combined liver-kidney transplant in, 812
    medical, 824–826
    postoperative disorders, 812–816
    preoperative disorders, 807–812
    GFR estimation in, 811–812
    intrinsic renal disease, 809–811
    prerenal azotemia, 807–808
    renal replacement therapy in, 812
  survival rate of, 821
Liver transplantation
  in cholangiocarcinoma management, 708–712
  extended donors in, 879–900. See also Liver transplant donors, extended donors
  for HBV, 753–764. See also Hepatitis B virus (HBV), liver transplantation for
  for HCC, 717–725. See also Hepatocellular carcinoma (HCC), liver transplantation for
  MELD score in
    application of, 688–691. See also Model for End-Stage Liver Disease (MELD) score, in liver transplantation, application of
    new-onset diabetes mellitus after, 816
    recurrent HCV infection after
      management of, 845–858. See also Hepatitis C virus (HCV) infection, recurrent, after liver transplantation, management of
      substance use disorders–related. See Substance use disorders, treatment of, liver transplantation in
    survival following, 821
Living donors
  extended donors in liver transplantation, 890–893
Lung cancer
  in liver transplant recipients
    medical management of, 834
Lymphoma(s)
  in liver transplant recipients
    medical management of, 835

M
Malignancy(ies). See also specific types
de novo
  in liver transplant recipients
    surveillance programs for, 835
  in liver transplant recipients
    medical management of, 832–835
previous
  extended donors in liver transplantation, 884–885
MELD score. See Model for End-Stage Liver Disease (MELD) score
Mental health evaluation
  in liver transplantation assessment for patients with substance use disorders, 731
Metabolic bone disease
  in liver transplant recipients
    medical management of, 830–832
Methadone-maintained liver transplant candidates, 738–739
Milan Criteria, 718–721
Model for End-Stage Liver Disease (MELD) score, 685–698
  components of, 686–688
    bilirubin, 686–687
    creatinine, 687–688
    INR, 688
  delta MELD, 692
  development of, 685–686
  improving, 691–694
  in liver transplantation
    application of, 688–691
      renal dysfunction, 689–690
    in benefit assessment, 690
    gender as factor in, 690–691
    for HCC, 718
    retransplantation-related, 691
  in non–liver transplant settings, 691
  reweighing components of, 693–694
  serum sodium incorporation in, 692–693

N
Naltrexone
  for substance use disorders, 733–734
New-onset diabetes mellitus after transplant (NODAT), 816
Nicotine replacement therapies (NRTs)
  in smoking cessation, 734
NODAT. See New-onset diabetes mellitus after transplant (NODAT)
NRTs. See Nicotine replacement therapies (NRTs)

O
Oropharynx
  carcinoma of
    in liver transplant recipients
      medical management of, 834
Osteopenia
  in liver transplant candidates, 791
Osteoporosis
  in liver transplant candidates, 791
P
Portopulmonary hypertension
in pretransplant patients, 770–772
Prerenal azotemia
in liver transplant recipients
management of, 807–808
Primary biliary cirrhosis, 859–863
described, 859–860
diagnosis of, 860–861
epidemiology of, 861
prognosis of, 863
recommendations, 863
recurrence of
predictors of, 861–863
survival rates for, 859
treatment of, 863
Primary sclerosing cholangitis, 863–868
described, 863–864
diagnosis of, 864–866
epidemiology of, 864–866
outcomes of, 866–868
recommendations, 868
recurrence of
predictors of, 866
treatment of, 868
Pulmonary disorders
in pretransplant patients, 765–777. See also Liver disease, pulmonary complications of, in pretransplant patients

R
Radiofrequency ablation (RFA)
for HCC in liver transplant candidates, 785
Rehabilitation
addiction
for addiction disorders, 732–733
Renal disease
intrinsic
in liver transplant recipients
management of, 809–811
Renal dysfunction
in liver transplant recipients
management of, 807–820. See also Liver transplant recipients, renal dysfunction in, management of medical, 824–826
liver transplantation–related
MELD score for, 689–690
Renal replacement therapy
for renal dysfunction in liver transplant recipients, 812
Retransplantation
  MELD score and, 691
RFA. See Radiofrequency ablation (RFA)

S
SBP. See Spontaneous bacterial peritonitis (SBP)
Serum sodium
  in MELD, 692–693
Skin cancer
  in liver transplant recipients
    medical management of, 833–834
Sleep-disordered breathing
  in pretransplant patients, 772
Smoking cessation
  medications for, 734–735
Split liver transplantation
  extended donors in liver transplantation, 889–890
Spontaneous bacterial peritonitis (SBP)
  in liver transplant candidates, 788–789
Steatosis
  extended donors in liver transplantation, 883–884
Substance use
  in liver transplant patients, 727–751
Substance use disorders
  assessment of, 730–731
  described, 728–730
  in end-stage liver disease populations, 728–730
  psychiatric diagnosis of, 730–731
  treatment of
    addiction rehabilitation in, 732–733
    liver transplantation in
      alcohol use on waitlist, 738
      controversial issues related to, 736–739
      ethical perspectives on, 736–737
      future directions in, 744–745
      listing criteria, 737–738
      methadone-maintained candidates, 738–739
      planning for, 730–731
        general recommendations, 730–731
        mental health evaluation in, 731
        timing of referral in, 731
        written behavioral contracts in, 731
      posttransplant monitoring, 735–736
      posttransplant outcomes, 739–740
      pretransplant monitoring, 735
      psychosocial aspects of, 739–740
      quality of life after, 739–740
      relapse rates after, 740–743
Substance (continued)
  third-party payer contributions, 739
  vascular complications of, 743
  medications in, 733–734
  monitoring in, 735–736
  options, 732–735
  verifying abstinence and participation in, 735–736
Surgical resection
  in cholangiocarcinoma management, 706–708

T
TACE. See Transarterial chemoembolization (TACE)
Tenofovir
  in pretransplant management in HBV patients, 755
Third-party payer contributions
  in liver transplantation for patients with substance use disorders, 739
Tobacco use
  after liver transplantation, 741–742
  cancer related to, 742–743
  in liver transplant candidates, 730
Transarterial chemoembolization (TACE)
  for HCC in liver transplant candidates, 785–786
Transplantation
  liver. See Liver transplantation
  liver-kidney
    for renal dysfunction in liver transplant recipients, 812
  split liver
    extended donors in liver transplantation, 889–890

U
United Network for Organ Sharing (UNOS)
  modified TNM staging classification of
    for primary HCC, 718
UNOS. See United Network for Organ Sharing (UNOS)

V
Vaccination
  for liver transplant candidates with chronic liver disease, 791–792
Varenicline
  in smoking cessation, 735
Viral load
  in pretransplant management in HBV patients, 753–756